What You Should Know;
– Boston Micro Fabrication (BMF) today announced the launch of BMF Biotechnology Inc., a dedicated subsidiary focused on developing and commercializing innovative BioChips – advanced microfluidic platforms that mimic human organs.
– By leveraging BioChip technology, BMF Biotechnology aims to accelerate breakthroughs in drug development, improve cosmetic safety and efficacy testing, and ultimately, contribute to the development of more effective treatments for patients.
BMF: A Legacy of Precision Microfabrication
BMF has established itself as a leader in high-precision micro-printing solutions for various industries, including medical devices, electronics, and life sciences. Their expertise in creating features with exceptional resolution and dimensional tolerance is a cornerstone of their success.
Expanding Beyond Printing: The Rise of BMF Biotechnology
In late 2022, BMF embarked on a strategic expansion. This initiative included the establishment of the San Diego Research Institute, dedicated to pioneering microfluidic BioChip technology for drug discovery and cosmetic testing. The initial phase of research has yielded highly promising results.
BioChips: A Powerful Platform for Advanced Research
BMF Biotechnology’s BioChips offer a revolutionary approach to studying human health and disease. By meticulously replicating the body’s physiological conditions, these platforms enable researchers to:
- Investigate biological mechanisms of health and disease
- Evaluate the safety and efficacy of drugs and cosmetics
- Predict patient responses to treatment
A key advantage of BioChips is their integrated “vascular-mimetic” network. This intricate system mimics the human body’s blood vessels, allowing for the delivery of nutrients, removal of waste products, and distribution of compounds throughout the entire tissue sample. This innovation has the potential to yield:
- More precise testing results
- Enhanced prediction of compound sensitivity compared to traditional 2D cell cultures and animal models
BMF Biotechnology Partner Program: Fostering Collaboration and Innovation
To fully unlock the potential of BioChips, BMF Biotechnology is actively recruiting collaboration partners. The BMF Biotechnology Partner Program provides a framework for joint development and validation of innovative devices and biological models. Industry, research institutions, and academia are all encouraged to reach out and explore potential partnerships.
“Building on success that BMF has had with other self-driven innovations such as the UltraThineer veneers, the launch of BMF Biotechnology Inc. represents a significant leap forward in our ability to harness the potential of 3D BioChip technology,” remarked Dr. Jennifer Sun, Chief Scientific Officer of BMF Biotechnology Inc. “With our innovative technology and approach, we aim to empower researchers with the tools they need to translate scientific discoveries into tangible therapeutic solutions that improve patient outcomes.”
